L-Theanine 200mg Lifts Alpha Waves 42% and Cuts GAD-7 by 29% in Chronic Anxiety — 8-Week RCT
WELLNESS

L-Theanine 200mg Lifts Alpha Waves 42% and Cuts GAD-7 by 29% in Chronic Anxiety — 8-Week RCT

By Aria · · https://www.mdpi.com/journal/nutrients
KO | EN

An 8-week RCT in chronic anxiety patients taking 200mg of green tea amino acid L-theanine showed EEG alpha wave amplitude rising 42% and GAD-7 anxiety dropping 29%. Published in the October 2025 issue of Nutrients, the joint trial by Tokyo Medical University and Taiyo Kagaku enrolled 96 GAD (generalized anxiety disorder) patients and demonstrated superiority over placebo across EEG, clinical, and physiological endpoints.

Researchers randomized 96 patients (mean age 35, 67% female, antidepressant-naive) meeting DSM-5 GAD criteria to Suntheanine standardized L-theanine 200mg (100mg morning + 100mg evening) or placebo. Primary endpoints were 8-week resting EEG alpha (8~13Hz) amplitude and GAD-7 score. Secondary endpoints were STAI state/trait anxiety, salivary cortisol, HRV, sleep (PSQI), and cognition (d2-R).

EEG alpha is the objective neurophysiological marker of relaxed-yet-attentive states. The L-theanine group’s resting alpha amplitude rose from 12.4 to 17.6 μV (+42%) versus +8% in placebo. Beta waves (anxiety/arousal marker) fell 18% with no change in theta (drowsiness marker). The alpha/beta ratio improved 51%, signaling a shift to “relaxed alertness” rather than simple sedation.

GAD-7 anxiety dropped from 14.2 to 10.1 (-29%) versus -8% in placebo. STAI state anxiety fell 24% and trait anxiety 19%. Salivary cortisol dropped 16% and HRV (SDNN) climbed from 38 to 46ms (+22%), restoring autonomic balance. Sleep quality (PSQI) improved 28% with sleep latency down 32%. Working memory (d2-R) rose 18%. Sedation and cognition improved together.

Detailed analysis showed acute effects (alpha +18% within 2 hours of single dose), 4-week cumulative effects (GAD-7 -18%), and 8-week peak. L-theanine has both acute relaxation and chronic anxiety-reduction properties. In a 12-week follow-up, effects sustained, and antianxiety drug initiation rate in the L-theanine group was four times lower than in placebo.

L-theanine is a non-protein amino acid isolated from green tea by Japan’s Tea Research Laboratory in 1949. Mechanisms include GABA-A receptor modulation, glutamate (NMDA) antagonism, dopamine and serotonin balance, and BDNF elevation. It crosses the blood-brain barrier and is detectable in the brain within 30 minutes. Suntheanine, standardized in 1994 by Taiyo Kagaku, is 100% L-isomer with clinically validated efficacy, unlike generic tea extracts containing D/L mixtures.

A cup of green tea contains 25~60mg of L-theanine. Achieving 200mg through diet requires 4~8 cups, which also delivers 100~200mg of caffeine. Caffeine reduces alpha waves, so chronic anxiety patients need a caffeine-free supplement form. Suntheanine is 0% caffeine and 99%+ L-isomer, making it the clinical reference for matrices.

Adverse events were 4.2% in the L-theanine group (mild headache, drowsiness) versus 4.1% in placebo, no significant difference. L-theanine is among the safest supplements documented. Japan’s Food Safety Commission set a 1,200mg/day upper safety limit. However, patients on antihypertensives, antidepressants (especially MAOIs), or pregnant women should consult a clinician. A 200mg dose over 6 weeks has already been validated for childhood ADHD.

Korean lifetime GAD prevalence in adults aged 20~40 is 5.7% per the 2026 mental health survey. Concerns about benzodiazepine dependency drive demand for non-pharmaceutical first-line matrices. L-theanine 200mg (Suntheanine) over 8~12 weeks is becoming standard in adults with normal ALT/AST, no antidepressant or antihypertensive use. When taken with caffeine (americano + L-theanine), it offsets caffeine’s tremor and anxiety, a documented synergy.